Seoulin Bioscience Company Limited operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seoulin Bioscience Company Limited with three other
companies in this sector in South Korea:
sales of 23.81 billion Korean Won [US$21.12 million]
of which 58%
Medipost Co Ltd
(42.25 billion Korean Won [US$37.48 million]
of which 46%
was Umbilical Cord Blood), and
(28.45 billion Korean Won [US$25.24 million]
During the year ended December of 2017, sales at
Seoulin Bioscience Company Limited were 42.62 billion Korean Won (US$37.80 million).
decrease of 5.1%
versus 2016, when the company's sales were 44.89 billion Korean Won.